RxDoctor Payments Data

Timothy Johnson

Optometrist · Los Alamos, NMNPI 1205826179

Payments from drug & device makers

$634in general payments, 2019–2025

Across 14 payments — averaging $45.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$219
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$115
  • Glaukos Corporation$113
  • Regeneron Healthcare Solutions, Inc.$66
  • Coherus Oncology, Inc.$49
  • Novartis$27
  • plus $44 from 2 others

What the payments were for

  • Food & beverage$634100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$634 in reported general payments places this provider in the 60th percentile of 228 optometrist providers in New Mexico.

See all optometrist providers in New Mexico

Medicare billing

Part B allowed, 2024
$210,906
Medicare patients
1,215
Services billed
2,447

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine56$63,996
LumiganBimatoprost71$25,620
Cyclosporine36$19,120
VyzultaLatanoprostene Bunod33$13,533
Fluorometholone105$7,942
RocklatanNetarsudil Mesylat/Latanoprost15$7,928
Latanoprost593$7,538
Prednisolone Acetate148$5,651
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat160$3,354
Loteprednol Etabonate11$2,572
Brimonidine Tartrate24$1,940
Timolol Maleate79$1,097
Dorzolamide Hcl34$661
Tobramycin-DexamethasoneTobramycin/Dexamethasone12$615
MoxifloxacinMoxifloxacin Hcl23$519

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$219$89,616127 claims
Bausch & Lomb Americas Inc.Vyzulta$17$13,53333 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$115$2,57211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 228 optometrist providers in New Mexico.

Other optometrist in Los Alamos

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →